| | □特定对象调研 □分析师会议 | | | | --- | --- | --- | --- | | 投资者关系活动类 | □媒体采访 □√业绩说明会 | | | | 别 | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称及人 | 投资者网上提问 | | | | 员姓名 | | | | | 时间 | 2025 年 5 月 13 日 (周二) 下午 15:00-17:00 | | | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网络 | | | | | 远程的方式召开业绩说明会 | | | | | 1、董事长 屠勇军 | | | | 姓名 | 3、副总经理兼董事会秘书 王艳 | | | | | 4、财务总监 王秀娟 | | | | 投资者关系活动主 | 感谢您的关注！公司 2025 年度 CDMO 业务收入 1.36 | | 亿元，较上年 | | 要内容介绍 | | | | | | 业务市场需求稳定；待产业化的 CDMO 项目受客户机构及项目上市、市 | | | ...

Group 1: Financial Performance - In Q1 2025, the company reported a revenue of 1.541 billion, representing a year-on-year growth of 10.1% [3] - The net profit attributable to shareholders was 327 million, with a year-on-year increase of 15.8% [3] - The net profit excluding non-recurring gains and losses grew by 20% year-on-year [3] Group 2: Business Segments - The small molecule CDMO business revenue remained flat, with a gross margin of 45.2% [3] - Emerging business revenue grew over 80% year-on-year, with a gross margin of 33.1% [3] - The company is focusing on expanding its capabilities in peptide, oligonucleotide, and ADC businesses [3] Group 3: Cost Management and Efficiency - The net profit growth outpaced revenue growth by 5.73 percentage points, indicating effective cost management [3] - The company is implementing cost reduction measures, resulting in a decrease in period expenses [3] - Capital expenditures will focus on emerging business areas, with limited new capital for small molecule capacity [3] Group 4: Market Outlook and Strategy - The company maintains a positive outlook for 2025, expecting double-digit revenue growth and net profit growth to exceed revenue growth [3] - There is confidence in achieving the revenue growth target based on current order coverage [4] - The company plans to enhance overseas capacity, particularly in Europe, to adapt to changing international circumstances [6] Group 5: Investor Engagement and Concerns - The company has engaged with over 240 participants from more than 100 institutions during the investor relations activity [2] - Concerns regarding the impact of the U.S. Biosecurity Act and tariff policies on business operations were addressed, indicating limited effects on competitiveness [4] - The company is actively managing supply chain challenges and maintaining communication with clients to ensure product delivery [4]